On June 25, 2026, Insight Holdings Group, LLC, along with its affiliated investment funds, collectively identified as the Insight entities, sold 530,982 shares of Hinge Health, Inc. (NASDAQ:HNGE) Class A Common Stock. The aggregate value of these transactions amounted to approximately $38.1 million. This divestment activity occurred against a backdrop of recent price appreciation for HNGE, which has climbed to $81.48, positioning the stock just below its 52-week high of $84.62.
According to analysis from InvestingPro, HNGE appears overvalued at its current trading levels and ranks among the platform’s most overvalued stocks. The analysis highlights that the stock is trading near its 52-week high, with additional insights available to subscribers through comprehensive Pro Research Reports covering Hinge Health and over 1,400 other US equities.
The sales followed the conversion of an equal number of Class B Common Stock shares into Class A Common Stock on the same day. Each share of Class B Common Stock is convertible at the holder’s option into one share of Class A Common Stock. This conversion automatically occurs upon certain events as outlined in Hinge Health’s amended and restated certificate of incorporation.
The Class A shares were sold in multiple transactions at prices ranging from $71.080 to $73.215 per share. Specifically, 441,140 shares were sold at weighted average prices ranging from $71.080 to $72.065. Another 55,826 shares were sold at weighted average prices between $72.100 and $73.095. The remaining 34,016 shares were sold at weighted average prices from $73.100 to $73.215. These sales were executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 20, 2025.
The Insight entities, identified as 10% owners of Hinge Health, include Insight Venture Partners X, L.P., Insight Venture Partners (Cayman) X, L.P., Insight Venture Partners (Delaware) X, L.P., and Insight Venture Partners X (Co-Investors), L.P. Insight Holdings Group, LLC is the sole shareholder of Insight Venture Associates X, Ltd., which is the general partner of Insight Venture Associates X, L.P., which in turn is the general partner of the aforementioned Insight Venture Partners funds. Jeffrey L. Horing, Deven Parekh, Jeffrey Lieberman, and Michael Triplett, as members of the board of managers of Insight Holdings Group, LLC, may be deemed to have shared voting and dispositive power over these shares, though they disclaim beneficial ownership except to the extent of their pecuniary interest.
In other recent news, Hinge Health has been the focus of several analyst updates following its Investor Day and Movement client conference. Canaccord raised its price target for Hinge Health to $76, maintaining a Buy rating, and highlighted the company’s growth outlook with expectations of adding 4 to 5 million covered lives during the 2026 selling season. Similarly, KeyBanc increased its price target to $90, citing new product offerings, including the addition of Surgery to HingeSelect. Citizens reaffirmed its Market Outperform rating and maintained an $80 price target after attending the company’s conference. Truist Securities also raised its price target to $85, expressing confidence in Hinge Health’s positioning for its next growth phase. Stifel reiterated a Buy rating and a $79 price target, emphasizing the company’s surgical expansion and revised long-term financial targets. These developments reflect the analysts’ positive outlook on Hinge Health’s strategic initiatives and potential growth trajectory.